BioSpace News Archive

Influential partners in diabetes, advocacy, and healthcare support effort to combat a nationwide insulin affordability crisis and increase accessibility.

CNS Pharmaceuticals, Inc. today reported its financial results for the year ended December 31, 2021 and provided a clinical update of its anti-cancer drug candidates currently in development for the treatment of primary and metastatic brain and CNS cancer.

Hyperfine, Inc. (Nasdaq: HYPR), the creator of Swoop®, the world’s first FDA-cleared portable MRI system™, today announced that it will report financial results for the fourth quarter and full year 2021 on Wednesday, March 23, 2022.

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China has approved the initiation of the CT041 confirmatory Phase II clinical trial for the treatment of patients with Claudin18.2 (CLDN18.2) positive advanced gastric /gastroesophageal junction cancer (GC/GEJ) who have failed at least 2 prior lines of systemic therapies.

Stereotaxis today reported financial results for the fourth quarter and full year ended December 31, 2021.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it is scheduled to attend two investor conferences during the month of March 2022.

LumiraDx Limited (Nasdaq:LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its fourth quarter and full year 2021 financial results on Thursday, March 10, 2022.

Albany NY, United States: The healthcare clinical analytics market is prognosticated to observe considerable growth on the back of numerous factors.

The global market for electric dental handpiece is growing due to the rising incidence of oral and dental problems.

Spexis AG announced that it has been awarded the second part of its phased funding grant from CARB-X, the global partnership led by Boston University dedicated to supporting the development of antibacterial products to diagnose, prevent and treat drug-resistant infections.